Chemokine receptors and their crucial role in human immunodeficiency virus infection: Major breakthroughs in HIV research

Scandinavian Journal of Immunology

Volumn 48, Issue 4, 1998, Pages 339-346

  Kristiansen, T B ^a   Knudsen, T B ^a   Eugen Olsen, J ^a  

^a Illinois   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RETROVIRUS; REVIEW; VIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION;

HIV INFECTIONS; HIV-1; HIV-2; HUMANS; RECEPTORS, CHEMOKINE; RECEPTORS, VIRUS; VIRUS REPLICATION;

EID: 0031783562     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1998.00438.x     Document Type: Review

References (80)

1. Barre-Sinoussi F, Chermann JC, Rey F et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868-71.
2. Gallo RC, Sarin PS, Gelmann EP et al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 1983;220:865-7.
3. Gelmann EP, Popovic M, Blayney D et al. Proviral DNA of a retrovirus, human T-cell leukemia virus, in two patients with AIDS. Science 1983;220:862-5.
4. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984;312:763-7.
5. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986;47:333-48.
6. Walker CM, Moody DJ, Stiles DP, Levy JA. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986;1234:1563-6.
7. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced hy CD8+ T cells. Science 1995;270:1811-5.
8. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-7.
9. Dragic T, Litwin V, Allaway GP et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381:667-73.
10. Deng H, Liu R, Ellmeier W et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-6.
11. Doranz BJ, Rucker J, Yi Y et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996;85:1149-58.
12. Owen SM, Ellenberger D, Rayfield M et al. Genetically divergent strains of human immunodeficiency virus type 2 use multiple coreceptors for viral entry. J Virol 1998;72:5425-32.
13. Jinno A, Shimizu N, Soda Y, Haraguchi Y, Kitamura T, Hoshino H. Identification of the chemokinereceptor TER1/CCR8 expressed in brain-derived cells and T cells as a new coreceptor for HIV-1 infection. Biochem Biophys Res Commun 1998;243:497-502.
14. Deng HK, Unutmaz D, KewalRamani VN, Littman DR. Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature 1997;388:296-300.
15. Choe H, Farzan M, Konkel M et al. The orphan seven-transmembrane receptor apj supports the entry of primary T-cell-line-tropic and dualtropic Human Immunodefidiency Virus type 1. J Virol 1998; 72:6113-8.
16. Samson M, Edinger AL, Stordeur P et al. ChemR23, a putative chemoattractant receptor, is expressed in monocyte-derived dendritic cells and macrophages and is a coreceptor for SIV and some primary HIV-I strains. Eur J Immunol 1998;28:1689-700.
17. Rollins BJ. Chemokines. Blood 1997;3:909-28.
18. Simmons G, Wilkinson D, Reeves JD et al. Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J Virol 1996;70:8355-60.
19. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1 infected individuals. J Exp Med 1997;185:621-8.
20. Karlsson A, Parsmyr K, Sandstrom E, Fenyo EM, Albert J. MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J Clin Microbiol 1994;32: 364-70.
21. Stent G, Joo GB, Kierulf P, Asjo B. Macrophage tropism: fact or fiction? J Leukoc Biol 1997;62:4-11.
22. Trkola A, Dragic T, Arthos J et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996;384:184-7.
23. Yanjie YI, Rana S, Turner JD, Gaddis N, Collman RG. CXCR-4 is expressed by primary macrophages and supports CCR-5 independent infection by dual-tropic but not T-tropic isolates of human immunodeficiency virus type 1. J Virol 1998;72:772-7.
24. Starcich BR, Hahn BH, Shaw GM et al. Indentification and characterization of conserved and variable regions of the envelope gene HTLV-III/LAV, the retroviruses of AIDS. Cell 1986;45:637-48.
25. Chesebro B, Nishio J, Perryman S et al. Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, macrophages. J Virol 1991;65:5782-9.
26. Shioda T, Levy JA, Cheng-Mayer C. Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1992;89:9434-8.
27. Hwang SS, Boyle TJ, Lyerly HK, Cullen BR. Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1. Science 1992;257:535-7.
28. Sattentau QJ, Moore JP, Vignaux F, Traincard F, Poignard P. Conformational changes induced in the glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding. J Virol 1993;67:7383-93.
29. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998;393:648-59.
30. Wyatt R, Kwong PD, Desjardins E et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998;393:705-11.
31. Rizutto CD, Wyatt R, Hern‡ndez-Ramos N et al. A conserved HIV gp120 Glycoprotein structure involved in chemokine receptor binding. Science 1998;280:1949-50.
32. Moore JP, Binley J. Envelope's letters boxed into shape. Nature 1998;393:630-1.
33. Moore JP, Cao Y, Leu J, Qin L, Korber B, Ho DD. Inter- and intraclade neutralization of human immunodeficiency virus type I: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol 1996; 70:427-44.
34. Choe H, Farzan M, Sun Y et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996; 85:1135-48.
35. Bjorndal A, Deng H, Jansson M et al. Coreceptor usage of primary human immunodeficiency virus type I isolates varies according to biological phenotype. J Virol 1997;71:7478-87.
36. Zhang L, Huang Y, He T, Cao Y, Ho DD. HIV-1 subtype and second-receptor use. Nature 1996; 383:768.
37. Berger EA, Doms RW, Fenyo EM et al. A new classification system for HIV-1. Nature 1998;391:240.
38. Aramori I, Zhang J, Ferguson SS, Bieniasz PD, Cullen BR, Caron MG. Molecular mechanism of desensitization of the chemokine receptor CCR-5: receptor signaling and internalization are dissociable from its role as an HIV-1 co-receptor. EMBO J 1997;16:4606-16.
39. Just JJ. Genetic predisposition to HIV-1 infection and acquired immune deficiency virus syndrome: a review of the literature examining associations with HLA. Hum Immunol 1995;44:156-69.
40. Liu R, Paxton WA, Choe S et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-77.
41. Samson M, Libert F, Doranz BJ et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382:722-5.
42. Stephens JC, Reich DE, Goldstein DB et al. Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes. Am J Hum Genet 1998;62:1507-15.
43. Libert F, Cochaux P, Beckman G et al. The delta ccr5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe. Hum Mol Genet 1998;7:399-406.
44. Iriarte M, Cornelis GR. Molecular determinants of yersinia pathogenesis. Microhiologia 1996;12:262-80.
45. Eugen-Olsen J, Iversen AK, Garred P et al. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS 1997;11:305-10.
46. Michael NL, Chang G, Louie LG et al. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997;3:338-40.
47. Meyer L, Magierowska M, Hubert JB et al. Early protective effect of CCR5 delta 32 heterozygosity on HIV-1 disease progression: relationship with viral load. AIDS 1997:11:F73-F78.
48. Dean M, Carrington M, Winkler C et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996;273:1856-62.
49. Garred P. Chemokine-receptor polymorphisms: clarity or confusion for HIV-1 prognosis. Lancet 1996;351:2-3.
50. Katzenstein T, Eugen-Olsen J, Iversen AK et al. HIV-infected individuals with the CKR5/CKR5 genotype have lower HIV RNA levels and higher CD4 cell counts in the early years of infection than do patients with the wildtype. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:10-4.
51. Garred P, Eugen-Olsen J, Iversen AK et al. Dual effect of CCR5 delta 32 gene deletion in HIV-1-infected patients. Lancet 1997; 349:1884.
52. Michael NL, Louie LG, Sheppard HW. CCR5-delta 32 gene deletion in HIV-1 infected patients. Lancet 1997;350:741-2.
53. Smith MW, Dean M, Carrington M, Huttley GA, O'Brien SJ. CCR5-delta 32 gene deletion in HIV-1 infected patients. Lancet 1997;350:741.
54. Quillent C, Oberlin E, Braun J et al. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet 1998;351:14-8.
55. Ansari-Lari MA, Liu XM, Metzker ML, Rut AR, Gibbs RA. The extent of genetic variation in the CCR5 gene. Nat Genet 1997; 16:221-2.
56. Smith MW, Dean M, Carrington M et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Science 1997;277:959-65.
57. Michael NL, Louie LG, Rohrbaugh AL et al. The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. Nat Med 1997;10:1160-2.
58. Eugen-Olsen J, Iversen AKN, Benfield TL, Koppelhus U, Garred P. Chemokine receptor CCR2b 64I polymorphism and its relation to CD4 counts and disease progression in HIV infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:110-6.
59. Mummidi S, Ahuja SS, Gonzalez E et al. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat Med 1998;4:786-93.
60. Kostrikis LG, Huang Y, Wolinsky SM et al. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med 1998;4:350-3.
61. Winkler C, Modi W, Smith MW et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. Science 1998; 279:389-93.
62. van Rij RP, Broersen S, Goudsmit J, Coutinho RA, Schuitemaker H. The role of a stromal cell-derived factor-1 chemokine gene variant in the clinical course of HIV-1 infection. AIDS 1998;12:F85-90.
63. Ioannidis JPA, O'Brien TR, Rosenberg PS, Contopoulos-Ioannidis DG, Goedert JJ. Genetic effects on HIV disease progression. Nat Med 1998;4:536.
64. Huang Y, Paxton WA, Wolinsky SM et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996;2:1240-3.
65. Zimmerman PA, Bucklerwhite A, Alkathaib G, Spanlding T, Kubofcik J, Combadiere C. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5 studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med 1997;3:23-6.
66. McNicholl JM, Smith DK, Qari SH, Hodge T. Host genes and HIV: the role of the chemokine receptor gene CCR5 and its allele. Emerg Infect Dis 1997;3:261-71.
67. Itescu S, Rose S, Dwyer E, Winchester R. Certain HLA-DR5 and -DR6 major histocompatibility complex class II alleles are associated with a CD8 lymphocytic host response to human immunodeficiency virus type I characterized by low lymphocyte viral strain heterogeneity and slow disease progression. Proc Natl Acad Sci USA 1994; 9:11472-6.
68. Naif HM, Li S, Alali M et al. CCR5 expression correlates with susceptibility of maturing monocytes to human immunodeficiency virus type 1 infection. J Virol 1998;72:830-6.
69. Wu L, Paxton WA, Kassam N et al. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med 1997;185:1681-91.
70. Moore JP. Coreceptors: implications for HIV pathogenesis and therapy. Science 1997;276:51-2.
71. Browning J, Horner JW, Pettoello-Mantovani M et al. Mice transgenic for human CD4 and CCR5 are susceptible to HIV infection. Proc Natl Acad Sci USA 1997;94:14637-41.
72. Simmons G, Clapham PR, Picard L et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997;276:276-9.
73. Hunter MG, Bawden L, Brotherton D et al. BB-10010: an active variant of human macrophage inflammatory protein-1 alpha with improved pharmaceutical properties. Blood 1995;86:4400-8.
74. de Roda Husman AM, Koot M, Cornelissen M et al. Association between CCR-5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997;127:882-90.
75. Bratt G, Leandersson AC, Albert J, Sandström E, Wahren B. MT-2 tropism and CCR-5 genotype strongly influence disease progression in HIV-1-infected individuals. AIDS 1998;12:729-36.
76. Yang AG, Bai X, Huang XF, Yao C, Chen S. Phenotypic knockout of HIV type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection. Proc Natl Acad Sci USA 1997;94:11567-72.
77. Chen JD, Bai X, Yang AG, Cong Y, Chen SY. Inactivalion of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy. Nat Med 1997;3:1110-6.
78. Berger EA. HIV entry and tropism: the chemokine receptor connection. AIDS 1997;11:S3-S16.
79. Cairns JS, D'Souza MP. Chemokines and HIV-1 second receptors: The therapeutic connection. Nat Med 1998;4:563-8.
80. Ghezzi S, Vicenzi E, Soldini L et al. Experiences in immune reconstitution. The rationale for interleukin-2 administration to HIV-infected individuals. J Biol Regul Homeost Agents 1997; 11:74-8.